US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process

As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.

Oil painting
Different strokes for different advisory committees • Source: Shutterstock

As the US Food & Drug Administration moves back to in-person advisory committees after four years of pandemic-induced virtual meetings, stakeholders are likely to see different approaches in how the panels are utilized by the drug and biologics product centers and the Oncology Center of Excellence.

While there is agreement on some big-picture issues – such as the need to return to in-person meetings – the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers